Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through PepGen’s science-laden disclosures can feel like sequencing DNA—especially when trial data, cash runway, and orphan-drug incentives are scattered across hundreds of pages. If you’ve ever searched for PepGen insider trading Form 4 transactions or wondered where the latest PepGen quarterly earnings report 10-Q filing hides key burn-rate figures, you’re not alone.
Stock Titan’s AI turns that tangle into clarity. Our real-time engine monitors every submission to EDGAR, then delivers PepGen SEC filings explained simply. Need an at-a-glance view of dose-escalation safety from an 8-K? We tag it automatically. Curious about PepGen Form 4 insider transactions real-time before the next data readout? Instant alerts arrive the moment executives move shares. Our platform also provides concise breakdowns of:
- PepGen annual report 10-K simplified—cash runway, EDO platform milestones, risk factors.
- Understanding PepGen SEC documents with AI—auto-generated summaries and side-by-side year-over-year metrics.
- PepGen 8-K material events explained—trial halts, partnership updates, or FDA feedback distilled into plain English.
- PepGen proxy statement executive compensation—gene-therapy expertise isn’t cheap; see how leadership is paid.
The result? PepGen earnings report filing analysis you can actually use. Track PepGen executive stock transactions Form 4 to spot confidence signals, compare segment R&D spend across quarters, and export data straight into your models. Complex biotech filings no longer require advanced genetics degrees—just Stock Titan’s precise AI summaries and real-time filing feed.
PepGen Inc. approved a company‑wide repricing of underwater employee stock options, effective
The repricing covers 3,557,903 option shares that previously had exercise prices ranging from
PepGen Inc.'s Schedule 13G shows that a group of Viking Global entities and three named executives report beneficial ownership of 3,482,434 shares of PepGen common stock, representing 5.1% of the 68,737,224 shares outstanding following the issuer's underwritten offering that closed on September 26, 2025. The filing states the shares are directly owned by Viking Global Opportunities Illiquid Investments Sub-Master LP and are subject to shared voting and shared dispositive power among the reporting persons. The filing includes a joint filing agreement and certifications that the holdings were not acquired to change or influence control.
Oxford Science Enterprises plc reports beneficial ownership of 4,955,388 shares of PepGen Inc. common stock, representing 7.21% of the outstanding shares based on the issuer's stated total of 68,737,224 shares. The reporting person discloses sole voting and sole dispositive power over these shares and indicates the holdings were not acquired to influence control of the issuer.
The statement references the issuer's prospectus supplement for the share count used to calculate the percentage and otherwise confirms no group affiliations, no shared voting or dispositive powers, and that the position is held directly by Oxford Science Enterprises plc.
Oxford Science Enterprises plc reported purchasing 200,000 shares of PepGen Inc. common stock on September 30, 2025 at $3.20 per share in the issuer's public offering. After the purchase, Oxford Science Enterprises beneficially owned 4,955,388 shares. The issuer disclosed there were 68,737,224 shares outstanding as of September 26, 2025, which means Oxford Science Enterprises no longer beneficially owns more than 10% of PepGen's common stock. As a result, Oxford Science Enterprises is no longer subject to Section 16 reporting obligations for PepGen common stock and indicated it will not file further Form 4 or Form 5 reports for these holdings.
PepGen Inc. (PEPG) is the subject of Amendment No. 4 to a Schedule 13D filed by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. Collectively the Reporting Persons beneficially own 20,099,753 shares, equal to 29.2% of the outstanding common stock based on 68,737,224 shares outstanding. The Fund acquired 9,375,000 shares in PepGen's 2025 public offering at $3.20 per share for an aggregate purchase price of $30.0 million, funded from the Fund's working capital. Certain employee options totaling up to 11,667 shares vest on schedule and a customary 60-day lock-up from the offering applies to directors and officers.
PepGen, Inc. (PEPG) disclosed an underwritten offering and related materials intended to fund its clinical programs and general corporate needs. The company says proceeds are expected to support the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials and for working capital and other general corporate purposes. The filing references an initial registration statement filed
PepGen Inc. is offering common stock at $3.20 per share to raise up to $100,000,000 (approximately $115,000,000 if the underwriters exercise their 30-day option in full for an additional 4,687,500 shares). Underwriting discounts of $0.192 per share (about $6,000,000 without option, $6,900,000 with option) are disclosed. Net proceeds are earmarked primarily to fund the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and general corporate purposes, with management retaining broad discretion over final allocation. Lock-up agreements apply to certain holders and may be released early at the underwriters’ discretion. PepGen’s common stock trades on Nasdaq under PEPG. The company completed a November 23, 2020 reorganization that made PepGen Inc. the sole shareholder of PepGen Limited and adopted PepGen Limited’s historical financial statements. As of September 24, 2025, PepGen sold 1,000,000 shares under an at-the-market program for gross proceeds of $10 million.
PepGen Inc. is offering shares of common stock and pre-funded warrants as described in this prospectus supplement. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001, does not expire, and includes ownership limitations (default 4.99%, elective 9.99%, adjustable up to 19.99% after 61 days). The prospectus warns purchasers of immediate dilution and potential further dilution from future issuances or option exercises. Proceeds are stated to fund FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and corporate purposes, though management retains broad discretion over allocation. The common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The document discloses underwriting arrangements, lock-up provisions, and U.S. and non-U.S. tax considerations for holders.
FAQ
What is the current stock price of PepGen (PEPG)?
What is the market cap of PepGen (PEPG)?
